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Fibrin opens the “gate” for leukocytes in the endothelium
Migration of blood leukocytes through the layer of endothelial cells into extravascular sites of inﬂammation is essential for host defense and
elimination of the consequences of tissue damage. The transendothelial migration of leukocytes has been shown to be promoted and mediated by
various cell adhesion receptors, such as selectins, ICAM-1, and integrins, as well as by multiple chemoattractant molecules [1–4]. Although many
aspects of leukocyte transmigration have been studied, some mechanisms, including a link between thrombosis and the recruitment of leukocytes to
sites of inﬂammation, remain not fully elucidated. In this issue of Thrombosis Research, an article by Yakovlev and Medved [5] has partially ﬁlled this
gap by clarifying the molecular basis for the previously discovered novel mechanism of leukocyte transmigration promoted by the interaction of
ﬁbrin with the very low density lipoprotein receptor (VLDLR) [6].
The role of ﬁbrin(ogen) and its derivatives in inﬂammation, including leukocyte transmigration, has been a matter of intensive investigations for
decades. Fibrinogen is one of the acute phase proteins up-regulated in response to injury and inﬂammation, followed by an up to ten-fold increase in
its concentration in blood [7]. Both ﬁbrinogen and ﬁbrin are involved in antimicrobial host protection, inﬂammatory reactions, wound healing, and
related pathophysiological processes [8–11]. Despite numerous data that point to a prominent role of ﬁbrin(ogen) in inﬂammation, the molecular
mechanisms of ﬁbrin(ogen)-mediated leukocyte transmigration remain unclear. So far, three main concepts have been put forward to explain the
role of ﬁbrin(ogen) in leukocyte transmigration, two of which are based on the physical bridging of leukocytes to the endothelium. First, it was
proposed that ﬁbrinogen links leukocytes to the endothelium through its interaction with the leukocyte receptor Mac-1 and endothelial cell receptor
ICAM-1, and that such bridging promotes transendothelial migration of leukocytes [12,13]. This mechanism has been questioned because of the fact
that soluble ﬁbrinogen is non-reactive with Mac-1, as discussed in the article by Yakovlev and Medved [5]. However, the binding speciﬁcity of
surface-adsorbed ﬁbrinogen may be distinct from that of its soluble form; therefore, such interaction could not be excluded. Second, it was suggested
that ﬁbrin degradation products could bridge leukocytes to the endothelium via their interaction with endothelial VE-cadherin and leukocyte
receptor CD11c, also known as the integrin αX subunit, thus promoting leukocyte transmigration [14]. In particular, the leukocyte migrating activity
was attributed to the ﬁbrin degradation product, fragment E1 [14,15]. However, the E1 fragment exists only as a part of the D-D:E1 complex, in which
knob ‘A’ (the αGly17-Pro18-Arg19 sequence), the active binding site of E1, is inaccessible for CD11c, which makes the E1-mediated intercellular
interaction unlikely, unless some other receptor(s) or portions of E1 are involved as alternative binding sites. The third mechanism of ﬁbrin(ogen)-
mediated leukocyte transmigration proposed earlier by the authors of the present study involves ﬁbrin whose interaction with VLDLR via the N-
terminal portions of ﬁbrin β chains, known as βN-domains, promotes leukocyte transmigration [6]. However, there was no direct experimental
evidence that ﬁbrin can stimulate leukocyte transmigration via this mechanism. Furthermore, it was unclear which ﬁbrin species, soluble ﬁbrin,
ﬁbrin polymers, or ﬁbrin degradation products, are involved in such stimulation. The current article by Yakovlev and Medved [5] addressed these
questions.
The authors performed a comprehensive and through study of the interaction of recombinant soluble VLDLR, which is normally expressed in
endothelial cells, with ﬁbrinogen, ﬁbrin, and their recombinant fragments corresponding to the ﬁbrin(ogen) (B)βN-domains. They also studied the
eﬀect of ﬁbrinogen, ﬁbrin, and various ﬁbrin-derived species on transendothelial migration of leukocytes. The authors demonstrated that freshly
puriﬁed monomeric ﬁbrinogen in solution does not bind to VLDLR and has practically no inﬂuence on leukocyte transmigration. However, ﬁ-
brinogen became highly reactive towards soluble VLDLR either in the adsorbed state or upon conversion to ﬁbrin, implying that the VLDLR-binding
site(s) is exposed due to conformational transitions. The study also revealed that the D-D:E1 complex, high molecular mass ﬁbrin degradation
products, soluble ﬁbrin, as well as insoluble ﬁbrin polymers deposited on the endothelium (endothelium-anchored ﬁbrin clots), promote leukocyte
transmigration in a VLDLR-dependent manner. These ﬁndings provide insights into the molecular and sub-molecular mechanisms underlying the
transendothelial migration of leukocytes in thrombotic inﬂammation and show that it is mediated mainly by the ﬁbrin-VLDLR interaction. Among
these ﬁndings, the most important one is that endothelium-anchored ﬁbrin clots promote leukocyte transmigration since it establishes an important
link between thrombosis and the recruitment of leukocytes to sites of inﬂammation. This link is demonstrated by a diagram in Fig. 1 providing a
summarized mechanistic explanation for the VLDLR-dependent transendothelial migration of leukocytes induced by a ﬁbrin clot deposited on the
endothelium, which follows from the article by Yakovlev and Medved [5]. Thus, the results presented in this article certainly have a remarkable
(patho)physiological signiﬁcance because they shed light on clinically and biologically important pathogenic processes underlying many diseases
and pathological conditions.
There are a few additional notable points that could be inferred from the article by Yakovlev and Medved [5]. First, this work aﬃrms that a
strong mechanistic interplay between inﬂammation and thrombosis is bidirectional. In other words, it shows that not only local inﬂammation can
enhance hemostatic and thrombotic processes by amplifying clot initiation and limiting ﬁbrinolysis [16], but that ﬁbrin formation and deposition on
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